Early research (Phase 1)Looking for participantsNCT07517198
What this trial is testing
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Who this might be right for
Solid TumorSmall Cell Lung Cancer (SCLC)High Grade Neuroendocrine Cancer+9 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. 40